MAP2K7 and cholangiocarcinoma: Yet, in unselected CCA populations, MEK-pathway suppression has not changed standard care: adding selumetinib to cisplatin/gemcitabine failed to improve efficacy and increased toxicity [49], and atezolizumab plus cobimetinib showed only modest progression-free survival gains with low response rates versus atezolizumab alone [50], while an immunotherapy triplet variation did not improve outcomes [51].